APLS Valuation

Apellis Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

19.890

+0.61(3.164%)1D

Overview
Forecast
Valuation
Earnings

APLS Relative Valuation

APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.

Historical Valuation

Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.82 is considered Undervalued compared with the five-year average of -19.63. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 72.70 to 83.94 according to relative valuation methord. Compared to the current price of 19.89 USD , Apellis Pharmaceuticals Inc is Undervalued By 72.64%.

Relative Value

Fair Zone

72.70-83.94

Current Price：19.89

72.64%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

14.75

P/B

Median3y

21.66

Median5y

16.78

-0.34

FCF Yield

Median3y

-7.85

Median5y

-8.47

Competitors Valuation Multiple

The average P/S ratio for APLS's competitors is 34.22, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 2.82, which is -91.76% above the industry average. Given its robust revenue growth of -3.21%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

APLS.O

Apellis Pharmaceuticals Inc

2.82

Average P/S: 34.22

-3.21%